July 12 Company Quick Takes: Emflaza could be cost-effective for DMD at highest threshold; plus Darzalex, Skyrizi, Forxiga
ICER gives Emflaza pricing more leeway in updated report
The Institute for Clinical and Economic Review released an updated evidence report on Duchenne muscular dystrophy therapies that increased its range of acceptable prices at which corticosteroid Emflaza deflazacort from PTC Therapeutics Inc. (NASDAQ:PTCT) could be considered cost effective. Based on the drug's net price of $81,400 per year, it falls under the $500,000 per quality-adjusted life year (QALY) threshold. The draft evidence report had previously found the drug's price exceeded that willingness-to-pay threshold. However, to meet the more common cost-effectiveness thresholds of $100,000-$150,000 per QALY, ICER found that Emflaza would need to cost between $19,900-$31,700 (see "ICER Questions Price of DMD Therapies").
Submission for subcutaneous Darzalex
Janssen Pharmaceuticals Inc. submitted a BLA to FDA for a subcutaneous formulation of Darzalex daratumumab to treat multiple myeloma...